<div id="readability-page-1"><p>Shikiar Asset Management Inc. decreased its holdings in shares of  Incyte Corporation (NASDAQ:INCY - Free Report) by 15.8% during the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor  owned 95,950 shares of the biopharmaceutical company's stock after selling 18,045 shares during the quarter. Incyte comprises about  2.0% of Shikiar Asset Management Inc.'s investment portfolio, making the stock its 15th largest position. Shikiar Asset Management Inc.'s holdings in Incyte were worth $8,138,000 at the end of the most recent quarter.</p><ul><li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li></ul><p>Other institutional investors have also bought and sold shares of the company. Czech National Bank lifted its stake in shares of  Incyte by 6.4% during the 2nd quarter. Czech National Bank now owns 39,271 shares of the biopharmaceutical company's stock worth $2,674,000 after acquiring an additional 2,378 shares during the last quarter.  denkapparat Operations GmbH grew its position in  Incyte by 46.1% in the 2nd quarter. denkapparat Operations GmbH now owns 11,292 shares of the biopharmaceutical company's stock valued at $769,000 after acquiring an additional 3,564 shares during the last quarter.  Hussman Strategic Advisors Inc. increased its stake in  Incyte by 20.0% in the second quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company's stock worth $4,290,000 after purchasing an additional 10,500 shares during the period.  Fisher Asset Management LLC increased its stake in  Incyte by 74.6% in the second quarter. Fisher Asset Management LLC now owns 29,922 shares of the biopharmaceutical company's stock worth $2,038,000 after purchasing an additional 12,785 shares during the period.  Finally, Strid Group LLC bought a new stake in shares of  Incyte during the second quarter worth $999,000. Institutional investors own  96.97% of the company's stock. </p><h2>Insiders Place Their Bets</h2><p>In other Incyte news, EVP Steven H. Stein sold 20,105 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the completion of the sale, the executive vice president directly owned 63,129 shares of the company's stock, valued at approximately $6,471,353.79. This represents a 24.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Tray sold 2,774 shares of the firm's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the sale, the insider owned 22,973 shares in the company, valued at $2,297,300. This represents a 10.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 88,318 shares of company stock valued at $8,708,893 in the last three months. 17.80% of the stock is currently owned by insiders. </p><h2>Key Incyte News</h2><ul><li>5 top healthcare stocks for earnings growth in 2024</li></ul><p>Here are the key news stories impacting Incyte this week:</p><ul>   <li><span>Positive Sentiment: </span>Japan approvals broaden commercial footprint — Japan's health authorities approved Zynyz® (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, opening incremental revenue opportunities in a major market. Read More. Read More.</li>    <li><span>Positive Sentiment: </span>Analyst momentum and price‑target lifts — Several firms have recently raised targets or upgraded INCY (examples cited include Guggenheim and Barclays), which supports a constructive medium‑term revenue/earnings narrative. Read More.</li>    <li><span>Neutral Sentiment: </span>Price action shows investor interest but cautions remain — A Zacks write‑up noted a ~5.5% prior session surge on above‑average volume but warned that recent earnings‑estimate revisions may limit near‑term upside, implying momentum may not be durable without further data. Read More.</li>    <li><span>Negative Sentiment: </span>Insider selling could add selling pressure — Director/officer Thomas Tray disclosed sales totalling 3,374 shares across Dec. 18–19 (avg. ~$98–$100) and other insider transactions were reported; concentrated insider sales can signal near‑term pressure or prompt investor caution. Read More.</li> </ul><h2>Incyte Stock Down 1.9%</h2><p>Shares of NASDAQ INCY opened at $100.71 on Tuesday. The company has a current ratio of 3.20, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $19.77 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 0.70 and a beta of 0.81. The stock's fifty day simple moving average is $98.53 and its two-hundred day simple moving average is $85.09. Incyte Corporation has a 12-month low of $53.56 and a 12-month high of $109.28. </p><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 EPS for the quarter, topping the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the company posted $1.07 EPS. The business's revenue for the quarter was up 20.0% compared to the same quarter last year.  As a group, analysts expect that  Incyte Corporation will post 4.86 EPS for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>Several research analysts recently commented on INCY shares. Stifel Nicolaus raised their price target on shares of Incyte from $110.00 to $115.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, September 22nd. Weiss Ratings  reaffirmed a &#34;hold (c+)&#34; rating on shares of Incyte in a research note on Wednesday, October 8th. Morgan Stanley boosted their price target on Incyte from $86.00 to $92.00 and gave the company an &#34;equal weight&#34; rating in a report on Monday, December 8th. Piper Sandler upped their target price on Incyte from $82.00 to $102.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, November 4th. Finally, Barclays increased their price target on Incyte from $101.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 24th. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, the stock  has a consensus rating of &#34;Hold&#34; and a consensus target price of $99.07.</p><p><b>Read Our Latest Stock Analysis on Incyte</b></p><h2>About Incyte</h2> (Free Report)<p>Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.  </p><p>The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.</p><h2>See Also</h2><ul><li>Five stocks we like better than Incyte</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>The Last Gold Bull Market </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Incyte Right Now?</h2><p>Before you consider Incyte, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

INCY

<p>Shikiar Asset Management Inc. reduced its stake in Incyte Corporation by 15.8% in Q3, selling 18,045 shares. Insider transactions include EVP Steven H. Stein selling 20,105 shares and insider Thomas Tray selling 2,774 shares. Incyte's stock opened at $100.71, with a market cap of $19.77 billion. Recent analyst upgrades and Japan approvals for key drugs may impact future earnings.</p>

Shikiar Asset Management Inc. Cuts Stock Position in Incyte Corporation $INCY